Pharmaceuticals: Major · attribution context sourced from stored price moves, stored event labels, and peer-relative residuals inside the XLV constituent company universe.
Review priority 100 · Source rank 0 · Volume 5.1x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -0.15% · Sector -0.34% · Industry +0.92% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -19.44%Review priority 100 · Source rank 0 · Volume 7.4x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +0.93% · Sector +0.62% · Industry -0.67% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +17.96%Review priority 77 · Source rank 0 · Volume 3.7x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +1.83% · Sector -2.30% · Industry -0.16% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -8.08%Review priority 72 · Source rank 54 · Volume 2.5x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +5.86% · Sector -2.61% · Industry -0.10% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +8.38%Review priority 72 · Source rank 54 · Volume 1.1x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -3.56% · Sector +3.05% · Industry +0.94% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -10.92%Review priority 72 · Source rank 54 · Volume 1.5x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +3.53% · Sector -2.29% · Industry -2.16% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +9.99%| Date | Label | Move | Residual after context | Scope | Confidence |
|---|---|---|---|---|---|
| Mar 17, 2020 | Broad market moved +5.86% with this stock | +11.54% | +8.38% | Macro | 58% |
| Mar 20, 2020 | Broad market moved -3.56% with this stock | -10.49% | -10.92% | Macro | 58% |
| May 12, 2025 | Broad market moved +3.53% with this stock | +9.07% | +9.99% | Macro | 58% |
| Oct 28, 2025 | Regeneron Pharmaceuticals, Inc. 8-K: 8-K | +11.82% | -1.09% | Direct | 70% |
| Oct 28, 2025 | Regeneron Pharmaceuticals, Inc. 10-Q: 10-Q | +11.82% | -1.09% | Direct | 70% |
| Oct 28, 2025 | NASDAQ:REGN 8-K current report items 2.02,9.01 | +11.82% | -1.09% | Direct | 94% |
| May 18, 2026 | Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN) | -9.82% | -0.95% | Direct | 80% |
| May 18, 2026 | Regeneron Pharma Is Maintained at Equal-Weight by Wells Fargo | -9.82% | -0.95% | Direct | 71% |
| May 18, 2026 | Regeneron Stock Tumbles on Melanoma Drug Trial Miss — WSJ | -9.82% | -0.95% | Direct | 71% |
| Oct 31, 2024 | Regeneron Pharmaceuticals, Inc. 10-Q: 10-Q | -9.17% | -0.75% | Direct | 70% |